Bibliography
- Fink DJ , WechuckJ, MataM et al. Gene therapy for pain: results of a Phase I clinical trial. Ann. Neurol. 70(2) , 207–212 (2011).
- Goss JR , MataM, GoinsWF, WuHH, GloriosoJC, FinkDJ. Antinociceptive effect of a genomic herpes simplex virus-based vector expressing human proenkephalin in rat dorsal root ganglion. Gene Ther.8(7) , 551–556 (2001).
- Goss JR , HarleyCF, MataM et al. Herpes vector-mediated expression of proenkephalin reduces pain-related behavior in a model of bone cancer pain. Ann. Neurol. 52 , 662–665 (2002).
- Hao S , MataM, GoinsW, GloriosoJC, FinkDJ. Transgene-mediated enkephalin release enhances the effect of morphine and evades tolerance to produce a sustained antiallodynic effect. Pain102 , 135–142 (2003).
- Wilson SP , YeomansDC, BenderMA, LuY, GoinsWF, GloriosoJC. Antihyperalgesic effects of infection with a preproenkephalin-encoding herpes virus. Proc. Natl Acad. Sci. USA96(6) , 3211–3216 (1999).
- Braz J , BeaufourC, CoutauxA et al. Therapeutic efficacy in experimental polyarthritis of viral-driven enkephalin overproduction in sensory neurons. J. Neurosci. 21(20) , 7881–7888 (2001).
- Meunier A , LatremoliereA, MauborgneA et al. Attenuation of pain-related behavior in a rat model of trigeminal neuropathic pain by viral-driven enkephalin overproduction in trigeminal ganglion neurons. Mol. Ther. 11(4) , 608–616 (2005).
- Yeomans DC , LuY, LauritoCE et al. Recombinant herpes vector-mediated analgesia in a primate model of hyperalgesia. Mol. Ther. 13(3) , 589–597 (2006).
- Wolfe D , HaoS, HuJ et al. Engineeringan endomorphin-2 gene for use in neuropathic pain therapy. Pain 133(1–3) , 29–38 (2007).
- Hao S , WolfeD, GloriosoJC, MataM, FinkDJ. Effects of transgene-mediated endomorphin-2 in inflammatory pain. Eur. J. Pain13 , 380–386 (2009).
- Hao S , MataM, WolfeD, GloriosoJC, FinkDJ. Gene transfer of glutamic acid decarboxylase reduces neuropathic pain. Ann. Neurol.57(6) , 914–918 (2005).
- Chattopadhyay M , MataM, FinkDJ. Vector-mediated release of GABA attenuates pain-related behaviors and reduces NaV1.7 in DRG neurons. Eur. J. Pain doi: 10.1016/j.ejpain.2011.03.007 (2011) (Epub ahead of print).
- Cope DK , LariviereWR. Gene therapy and chronic pain. ScientificWorldJournal6 , 1066–1074 (2006).
- Xu Y , GuY, XuGY, WuP, LiGW, HuangLY. Adeno-associated viral transfer of opioid receptor gene to primary sensory neurons: a strategy to increase opioid antinociception. Proc. Natl Acad. Sci. USA100(10) , 6204–6209 (2003).
- Storek B , ReinhardtM, WangC et al. Sensory neuron targeting by self-complementary AAV8 via lumbar puncture for chronic pain. Proc. Natl Acad. Sci. USA 105(3) , 1055–1060 (2008).
- Mata M , ChattopadhyayM, FinkDJ. Gene therapy for the treatment of sensory neuropathy. Expert Opin. Biol. Ther.6(5) , 499–507 (2006).
- Burgess G , WilliamsD. The discovery and development of analgesics: new mechanisms, new modalities. J. Clin. Invest.120(11) , 3753–3759 (2010).
- Kissin I . The development of new analgesics over the past 50 years: a lack of real breakthrough drugs. Anesth. Analg.110(3) , 780–789 (2010).
- Premkumar LS , SikandP. TRPV1: a target for next generation analgesics. Curr. Neuropharmacol.6(2) , 151–163 (2008).
▪ Website
- Clinical Trials. Identifier NCT01291901 www.clinicaltrials.gov